HC Wainwright Initiates Coverage on Sarepta Therapeutics (NASDAQ:SRPT)

Analysts at HC Wainwright initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The brokerage set a “sell” rating and a $80.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential downside of 29.97% from the company’s current price.

SRPT has been the subject of a number of other research reports. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Citigroup dropped their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Robert W. Baird decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Finally, Evercore ISI dropped their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $176.73.

Sarepta Therapeutics Trading Up 3.4 %

NASDAQ SRPT opened at $114.23 on Monday. The stock has a market cap of $10.91 billion, a P/E ratio of 91.38 and a beta of 0.81. The company’s fifty day simple moving average is $122.00 and its 200-day simple moving average is $131.52. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 52 week low of $78.67 and a 52 week high of $173.25.

Insider Buying and Selling at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 14.99 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Riggs Asset Managment Co. Inc. raised its position in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the period. CIBC Asset Management Inc raised its holdings in Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after buying an additional 86 shares during the period. EP Wealth Advisors LLC lifted its stake in Sarepta Therapeutics by 2.1% in the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after buying an additional 103 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of Sarepta Therapeutics by 1.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock worth $1,000,000 after acquiring an additional 120 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in shares of Sarepta Therapeutics by 3.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after acquiring an additional 145 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.